Page last updated: 2024-11-04

tiopronin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tiopronin: Sulfhydryl acylated derivative of GLYCINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5483
CHEMBL ID1314
CHEBI ID32229
SCHEMBL ID19989
MeSH IDM0013445

Synonyms (133)

Synonym
AC-2087
n-(2-mercaptopropanoyl)glycine
meprin (detoxicant)
tiopronino [inn-spanish]
ccris 1935
tiopronin [inn:dcf:jan]
(2-mercaptopropionyl)glycine
vincol
thiopronin
einecs 217-778-4
sutilan
tioproninum [inn-latin]
thiolpropionamidoacetic acid
captimer
thiopronine
tioglis
tiopronine [inn-french]
glycine, n-(2-mercapto-1-oxopropyl)-
brn 1859822
glycine, n-(2-mercaptopropionyl)-
n-(2-mercapto-1-oxopropyl)glycine
1953-02-2
tiopronin
acadione
capen
2-(2-sulfanylpropanoylamino)acetic acid
n-(2-mercaptopropionyl)glycine
thiosol
epatiol
mucolysin
thiola
NCGC00159422-02
thiola (tn)
tiopronin (jan/inn)
D01430
T2614
FT-0653686
chebi:32229 ,
CHEMBL1314 ,
nsc-760416
2-thiol-propionamido-acetic acid
2 thiolpropionamidoacetic acid
2-thiolpropionamidoacetic acid
acid, 2-thiolpropionamidoacetic
2 mercaptopropionylglycine
acid, 2-thiol-propionamido-acetic
alpha-mercaptopropionylglycine
tiopronine
alpha mercaptopropionylglycine
2-mercaptopropionylglycine
2 thiol propionamido acetic acid
bdbm50020805
(2-mercapto-propionylamino)-acetic acid
NCGC00159422-03
NCGC00159422-04
HMS3264B11
nsc 760416
unii-c5w04go61s
c5w04go61s ,
tioproninum
tiopronino
tox21_111654
dtxsid4023678 ,
dtxcid803678
cas-1953-02-2
A813794
pharmakon1600-01506190
nsc760416
FT-0603530
S2062
AKOS015895408
tiopronin [mart.]
tiopronin [who-dd]
thiola ec
tiopronin [jan]
tiopronin [inn]
tiopronin [mi]
tiopronin [orange book]
mercaptopropionylglycine-
tiopronin [vandf]
CCG-214007
HY-B0373
2-mercapto-propionylglycine
n-(2-mercaptopropanoyl) glycine
alpha-mercaptopropionyl glycine
n-(2-mercaptopropionyl) glycine
tiopronin, dextiopronin, tiopronin (n-2-mercaptopropionyl glycine)
MLS006010632
smr001550282
SCHEMBL19989
tox21_111654_1
mfcd00004861
tiopronin (thiola)
n-(2-sulfanylpropanoyl)glycine
(2-mercaptopropionylamino)acetic acid
AB00376096_02
sr-01000942263
SR-01000942263-1
(2-mercaptopropanoyl)glycine
tiopronin, vetranal(tm), analytical standard
n-(2-mercaptopropionyl)glycine, 99%
HMS3655L15
a-mercaptopropionyl glycine
tiopronin; 2-(2-sulfanylpropanoylamino)acetic acid
J-012651
SW219206-1
DB06823
2-(2-mercaptopropanamido)acetic acid
Q414456
glycine, n-(2-mercapto-1-oxopropyl)- (9ci)
AS-12522
BCP13354
acadione; capen; epatiol; vincol
AMY39003
2-(2-sulfanylpropanamido)acetic acid
C73708
(s)-2-(2-mercaptopropanamido)acetic acid
SY262996
mfcd30157366
EN300-7408657
2-(2-mercaptopropanamido)aceticacid
Z2681891170
(+)-(2-mercaptopropanoyl)glycine
2254742-23-7
(-)-(2-mercaptopropanoyl)glycine
2254742-22-6
tioproninum (inn-latin)
tiopronine (inn-french)
tiopronin (mart.)
tiopronino (inn-spanish)
tiopronin base
tiopronina
g04bx16

Research Excerpts

Overview

Tiopronin (MPG) is a thiol antioxidant drug that has been explored as a treatment for various oxidative stress-related disorders. It is mainly used for the treatment of cystinuria.

ExcerptReferenceRelevance
"Tiopronin is a widely used drug for treatment of cystinuria, rheumatoid arthritis and hepatic disorders. "( Detection of tiopronin in body fluids and pharmaceutical products using red-emissive DNA-stabilized silver nanoclusters as a fluorescent probe.
Jia, C; Luo, H; Ma, X; Tan, X; Wang, Y; Zhang, P; Zhao, Y, 2019
)
2.33
"Tiopronin is an antioxidant. "( Protective effects of tiopronin against oxidative stress in severely burned patients.
Chen, X; Chen, Z; Hu, XH; Qin, FJ; Shen, YM, 2019
)
2.27
"Tiopronin (MPG) is a thiol antioxidant drug that has been explored as a treatment for various oxidative stress-related disorders. "( Protective effects of tiopronin on oxidatively challenged human lung carcinoma cells (A549).
Beltz, J; Chernatynskaya, A; Ercal, N; Pfaff, A, 2020
)
2.32
"Tiopronin is a drug that is mainly used for the treatment of cystinuria."( Influence of Tiopronin on the Metabolism of Alcohol in Healthy Subjects.
Gabor, E; Kardel, B; Kroll, M; Merges, F; Nass, F; Schneider, B; Wilm, S, 2017
)
1.55
"Tiopronin (TP) is a synthetic thiol compound without chromophore. "( Quantitative determination of tiopronin in human plasma by LC-MS/MS without derivatization.
Jiang, X; Jin, Y; Li, C; Liu, C; Xu, H; Yuan, B; Zhai, N, 2012
)
2.11

Effects

ExcerptReferenceRelevance
"Tiopronin has been investigated therefore for its protective effects in rats in vivo."( Tiopronin protects against the nephrotoxicity of cisplatin in the rat.
Esposito, M; Lindup, WE; Viale, M; Zhang, JG, 1999
)
2.47

Actions

ExcerptReferenceRelevance
"Tiopronin suppressed increase in serum transaminase activity, accumulation of liver triglyceride and decrease of liver glucose-6-phosphatase activity induced by CCl4."( [Effect of thiol compounds on experimental liver damage (I). Preventive effect of tiopronin (2-mercaptopropionylglycine) on liver damage induced by carbon tetrachloride (author's transl)].
Chiba, T; Horiuchi, M; Nomura, M; Takase, K, 1979
)
1.21

Treatment

ExcerptReferenceRelevance
"Treatment with tiopronin could exert protective effects against burn-induced oxidative tissue damage and multiple-organ dysfunction, and also could reduce the volume of required fluid resuscitation in severely burned patients."( Protective effects of tiopronin against oxidative stress in severely burned patients.
Chen, X; Chen, Z; Hu, XH; Qin, FJ; Shen, YM, 2019
)
1.18

Toxicity

The toxic effect and antitumor activity of neocarzinostatin (NCS) and SMANCS [copoly(styrenemaleic acid)-conjugated NCS] were greatly affected by N-(2-mercaptopropionyl)-glycine [tiopronin] Both in vitro and in vivo, in cultured HeLa cells and RL male 1 tumor-bearing mice.

ExcerptReferenceRelevance
"The toxic effect and antitumor activity of neocarzinostatin (NCS) and SMANCS [copoly(styrenemaleic acid)-conjugated NCS] were greatly affected by N-(2-mercaptopropionyl)-glycine [tiopronin] both in vitro and in vivo, in cultured HeLa cells and RL male 1 tumor-bearing mice."( Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.
Maeda, H; Miki, T; Oda, T; Yamamoto, H, 1989
)
0.74
"Many of the adverse reactions produced by penicillamine and other compounds with an active sulfhydryl group form a distinctive pattern when viewed as a class."( Adverse effects profile of sulfhydryl compounds in man.
Jaffe, IA, 1986
)
0.27
" To prevent these adverse side effects without changing the anticancer activity of the drug, we attempted to apply the two-route-infusion chemotherapy using NCS and antidotes for the NCS treatment devised by Baba."( [Screening for antagonistic agents to the lethal toxicity of neocarzinostatin. II. Effects of various drugs in inhibiting the toxicity of neocarzinostatin in vivo].
Baba, T; Matsumoto, T; Ouchi, M; Toriyama, K, 1988
)
0.27
" As well as its effect in reducing the formation of the reactive metabolite, DTT has a potent protective effect against the toxic processes initiated by the APAP reactive metabolite."( Comparison of the protective effects of N-acetylcysteine, 2-mercaptopropionylglycine and dithiothreitol against acetaminophen toxicity in mouse hepatocytes.
Harman, AW; Self, G, 1986
)
0.27
" The most important major side effect was renal toxicity."( Clinical efficacy and adverse effects of tiopronin in rheumatoid arthritis. Report of a follow-up in 50 patients.
Ambanelli, U; Ferraccioli, GF; Manganelli, P,
)
0.4
" Pretreatment of slices with tiopronin for 60 min also significantly protected the renal slices from cisplatin-induced toxic effects."( Tiopronin protects against the nephrotoxicity of cisplatin in rat renal cortical slices in vitro.
Lindup, WE; Zhang, JG, 1996
)
2.03
"We have previously reported that the thiol compound tiopronin protects rat kidneys in vitro against the toxic activity of cisplatin."( Cisplatin combined with tiopronin or sodium thiosulfate: cytotoxicity in vitro and antitumor activity in vivo.
Esposito, M; Lindup, WE; Mariggiò, MA; Pastrone, I; Viale, M; Zhang, JG, 1999
)
0.86
"Protective efficacy of MPG (2-mercaptopropionyl glycine) was studied against the toxic effects of lead acetate in Swiss albino mice."( Lead induced spermatoxicity in mouse and MPG treatment.
Agarwal, K; Gautam, AK; Kumar, S; Saiyed, HN; Shah, BA, 2001
)
0.31
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"To evaluate medical treatments, in terms of adverse events (AEs) and therapeutic goals, in a large series of patients with cystinuria."( Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France.
Bataille, P; Bridoux, F; Brignon, P; Choquenet, C; Cochat, P; Combe, C; Conort, P; Courbebaisse, M; Daudon, M; Decramer, S; Doré, B; Dussol, B; Essig, M; Friedlander, G; Frimat, M; Gaunez, N; Jais, JP; Joly, D; Knebelmann, B; Le Toquin-Bernard, S; Lebbah, S; Lillo-Le Louët, A; Méjean, A; Meria, P; Morin, D; N'Guyen, HV; Normand, M; Pietak, M; Pontoizeau, C; Prot-Bertoye, C; Ronco, P; Saussine, C; Tostivint, I; Traxer, O; Tsimaratos, M, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic disposition of 2-mercaptopropionylglycine (2-MPG) given as a single intravenous injection and/or as a single oral dose was studied in 9 normal and 13 cystinuric dogs."( Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs.
Denneberg, T; Emanuelsson, BM; Hoppe, A; Kågedal, B; Lindgren, S, 1991
)
0.28
" Cmax was reached after 3-6 h, and after a shorter beta-phase a long terminal half-life of 53 h of total tiopronin was found."( Pharmacokinetics of oral tiopronin.
Carlsson, MS; Denneberg, T; Emanuelsson, BM; Kågedal, B; Lindgren, S, 1993
)
0.8

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability (FAUC) was 88 +/- 20% in normal dogs."( Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs.
Denneberg, T; Emanuelsson, BM; Hoppe, A; Kågedal, B; Lindgren, S, 1991
)
0.28
" Absolute bioavailability (f) was 63%, and bioavailability calculated from urinary excretion was 47%, which are well correlated with each other."( Pharmacokinetics of oral tiopronin.
Carlsson, MS; Denneberg, T; Emanuelsson, BM; Kågedal, B; Lindgren, S, 1993
)
0.59
" Recently a new method has been proposed to determine absolute bioavailability in the absence of intravenous dose."( Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view.
Mahmood, I, 1997
)
0.3
" The relative bioavailability of tiopronin enteric capsule was 103."( [Bioequivalence of tiopronin enteric capsules in healthy volunteers].
Qian, ZY; Tang, WY; Xiang, Y; Xu, CY; Yang, BB; Yang, L; Yuan, J; Zheng, H, 2009
)
0.96
" The present study demonstrated that iNOS-derived superoxide generation was reduced, and that the NO bioavailability was increased, by treatment with the NOS-cofactor, tetrahydrobiopterin (BH4), before I/R in the hearts isolated from diabetic rats."( Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart.
Fujita, M; Ito, S; Iwasaka, T; Katano, T; Okazaki, T; Otani, H; Shimazu, T; Yoshioka, K, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Tiopronin and D-penicillamine (50 mg/kg) do not exhibit anti-inflammatory effects in classic animal models (carragenin oedema, granuloma cotton pellets) When given with a long-lasting dosing regime. In dogs with re-formed cystine uroliths, dissolution may be induced by increasing the tiopronsin dosage to 40 mg/ kg body weight per day.

ExcerptRelevanceReference
" In contrast, an acceleration of the growth and a reduction of the survival time were observed in females dosed with alpha-MPG or DPA."( [Effect of alpha-mercaptopropionylglycine (alpha-MPG) and sodium dipropylacetate (DPA) on antibody formation (IV). Tumor immunity (author's transl)].
Koda, A; Mori, H; Saiki, I, 1978
)
0.26
" A relatively high dosage resulted in a reduction of the cytinuria."( [Cystine stone therapy with mercapto-propyonyl-glycine (MPG) (Thiola) (author's transl)].
Stuhlsatz, HW; Terhorst, B, 1975
)
0.25
"A simple and fast high-performance liquid chromatographic method was developed for the simultaneous measurement of 2-mercaptopropionylglycine (Tiopronine) and its metabolite (2-mercaptopropionic acid) in human plasma after the administration of a pharmaceutical dosage form (Acadione)."( Determination of 2-mercaptopropionylglycine and its metabolite, 2-mercaptopropionic acid, in plasma by ion-pair reversed-phase high-performance liquid chromatography with post-column derivatization.
Bannwarth, B; Gavriloff, C; Hercelin, B; Leroy, P; Matt, M; Mazza, M; Netter, P; Nicolas, A, 1991
)
0.48
" Leu-thiorphan shifted the dose-response curve to SP to lower concentrations."( Enkephalinase inhibitor potentiates substance P- and electrically induced contraction in ferret trachea.
Borson, DB; Nadel, JA; Sekizawa, K; Tamaoki, J, 1987
)
0.27
" Leucine-thiorphan shifted, in concentration-dependent fashions, the dose-response curves to all tachykinins to lower concentrations."( Enkephalinase inhibitor potentiates mammalian tachykinin-induced contraction in ferret trachea.
Basbaum, CB; Borson, DB; Graf, PD; Nadel, JA; Sekizawa, K; Tamaoki, J, 1987
)
0.27
" Similarly, chronic dosing with acetorphan after withdrawal produced no significant effect on body weight."( Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.
Livingston, SJ; Rooney, KF; Sewell, RD; Smith, HJ, 1988
)
0.27
" Administered prior to a non-fat meal, thiorphan (1 mg/kg) stimulated gastric emptying and inhibited it at higher dosage (10 mg/kg)."( Influence of enkephalinase inhibitors on gastric emptying in mice depends on the nature of the meal.
Buéno, L; Liberge, M; Rivière, PM, 1988
)
0.27
" We concluded that 2-MPG is well tolerated and promising for treatment of cystinuric dogs, but the pharmacokinetic studies should be expanded to include different dosage regimens, and results of long-term treatment should be evaluated."( Treatment of clinically normal and cystinuric dogs with 2-mercaptopropionylglycine.
Denneberg, T; Hoppe, A; Kågedal, B, 1988
)
0.27
"Tiopronin (50 mg/kg) and D-penicillamine (50 mg/kg) do not exhibit anti-inflammatory effects in classic animal models (carragenin oedema, granuloma cotton pellets) but suppress pertussis vaccine oedema, an immunological model, when given with a long-lasting dosing regime."( Some pharmacological properties of tiopronin.
Capasso, F, 1981
)
1.98
" The dose of the drug was on average, 1 gram daily, which, in one series of patients, was administered at the start of treatment and in another series, with an increase of dosage of 250 mg every 20 days."( [Tiopronine: new basic treatment for rheumatoid arthritis. Open study of 158 cases].
Barbieri, P; Ciompi, ML; Colamussi, V; Mazzoni, MR; Pasero, G; Pellegrini, P, 1980
)
1.17
" In vitro studies were performed to obtain the optimal dosage of the antioxidants N-(2-mercaptopropionyl)-glycine and and catalase to be used in subsequent in vivo experimental studies; cardiac homogenates were incubated in 0 to 5 mmol/L concentrations of the oxidant t-butylhydroperoxide and malondialdehyde production was measured."( Studies of hypoxemic/reoxygenation injury: without aortic clamping. VI. Counteraction of oxidant damage by exogenous antioxidants: N-(2-mercaptopropionyl)-glycine and catalase.
Buckberg, GD; Ihnken, K; Morita, K; Sherman, MP; Young, HH, 1995
)
0.29
" These findings, together with previously reported data, suggest that treatment should be initiated in a dosage of 1 g/day and that thiopronin-related adverse events are not dose-dependent."( [A comparative controlled trial of 2 administration modalities of tiopronin in rheumatoid arthritis].
Brin, S; Combe, B; Delecoeuillerie, G; Paolozzi, L; Sany, J, 1993
)
0.52
" In dogs with re-formed cystine uroliths, dissolution may be induced by increasing the tiopronin dosage to 40 mg/kg body weight per day."( Cystinuria in the dog: clinical studies during 14 years of medical treatment.
Denneberg, T; Hoppe, A,
)
0.35
"We determined the efficacy of alpha-mercaptopropionyl-glycine administered in a low dosage continuously or every other day for prophylaxis of cystine calculosis."( Prophylaxia of cystine calculosis by alpha-mercaptopropionyl-glycine administered continuously or every other day.
Berio, A; Piazzi, A,
)
0.13
" Drug dosage was adjusted to maintain free urine cystine level below 100 micromol/mmol creatinine."( Cystinuria in children and young adults: success of monitoring free-cystine urine levels.
Dello Strologo, L; Laurenzi, C; Legato, A; Pastore, A, 2007
)
0.34
"Appropriate dosing of cystine-binding thiol drugs in the management of cystinuria has been based on clinical stone activity."( Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.
Asplin, JR; Enders, FT; Goldfarb, DS; Malieckal, DA; Mara, K; Modersitzki, F, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.00000.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency3.46710.007215.758889.3584AID1224835
Fumarate hydrataseHomo sapiens (human)Potency11.77040.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency22.53580.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency37.22120.001310.157742.8575AID1259252; AID1259253
polyproteinZika virusPotency11.77040.00308.794948.0869AID1347053
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)1.90000.00001.612910.0000AID37654; AID37669
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (190)

Assay IDTitleYearJournalArticle
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1205942Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2216 expressing VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205942Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2216 expressing VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID37654Inhibition of the activity of rabbit lung Angiotensin I converting enzyme1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Angiotensin-converting enzyme inhibitors: new orally active 1,4-thiazepine-2,5-diones, 1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones possessing antihypertensive activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID695861Cytotoxicity against drug-resistant human NCI-ADR-RES cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695876Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695874Cytotoxicity against drug-resistant human KB-A1 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695826Reduction in ABCB1 mRNA transcripts in human HeLa MDR Tet-off cells at 1 mM incubated for 72 hrs by Northern blotting2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695823Reduction in ABCB1 mRNA transcripts in human HeLa MDR Tet-off cells at 1 mM incubated for 48 hrs by qRT-PCR2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695831Inhibition of P-gp by ATPase assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695846Resistance index, ratio of IC50 for CHO cells to IC50 for drug-resistant Chinese hamster 10576 cells expressing alpha tubulin mutant2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695854Cytotoxicity against drug-resistant human H460/MX50 cells expressing ABCG2 incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695843Resistance index, ratio of IC50 for human OVCAR8 cells to IC50 for drug-resistant human NCI-ADR-RES cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID695878Cytotoxicity against drug-resistant human KB-8-5 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695839Resistance index, ratio of IC50 for human H460 cells to IC50 for drug-resistant human H460/MX20 cells expressing ABCG22011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695877Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID695820Reduction in P-gp protein expression in human HeLa MDR Tet-off cells at 1 mM incubated for 24 hrs by Western blotting2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205924Inhibition of hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205924Inhibition of hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695848Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for pleotropic drug-resistant human CP20 cells2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695868Cytotoxicity against 10001 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695838Resistance index, ratio of IC50 for CHO cells to IC50 for drug-resistant Chinese hamster C5 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID695857Cytotoxicity against drug resistant human HEK293 cells expressing MRP1 incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695872Cytotoxicity against pleotropic drug-resistant human CP20 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695859Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205941Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205941Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring VIM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1205938Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2301 expressing NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205938Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2301 expressing NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695867Cytotoxicity against drug-resistant Chinese hamster 10576 cells expressing alpha tubulin mutant incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695851Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KBV1 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205929Binding affinity to hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205929Binding affinity to hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205936Antibacterial activity against Klebsiella pneumoniae T2216 expressing VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205936Antibacterial activity against Klebsiella pneumoniae T2216 expressing VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID695827Reduction in ABCB1 mRNA transcripts in human HeLa MDR Tet-off cells at 1 mM incubated for 48 hrs by Northern blotting2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695856Cytotoxicity against human H460 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID695821Reduction in ABCB1 mRNA transcripts in human KBV1 cells2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID695853Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KB-8-5 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID695866Cytotoxicity against mouse NIH/3T3 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695824Reduction in ABCB1 mRNA transcripts in human HeLa MDR Tet-off cells at 1 mM incubated for 24 hrs by qRT-PCR2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID37669In vitro inhibitory activity against rabbit lung Angiotensin I converting enzyme at pH 8.31985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives.
AID695836Inhibition of P-gp in human KB-V1 cells assessed as effect on rhodamine 123 efflux at 20 mM2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205939Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205939Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695865Cytotoxicity against drug-resistant mouse G185 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID695871Cytotoxicity against CHO cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695875Cytotoxicity against drug-resistant human KB-8-5-11 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695832Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs in presence of P-gp inhibitor cyclosporin A by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695829Cytotoxicity against drug-resistant human MCF7/VP16 cells expressing MRP1 incubated for 72 hrs in presence of MRP1 inhibitor MK571 by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID696025Potentiation of paclitaxel-induced cytotoxicity in human KBV1 cells pre-incubated at 5 mM for 6 weeks before doxorubicin addition relative to untreated paclitaxel control2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID695844Resistance index, ratio of IC50 for human HeLa Tet-off cells to IC50 for drug-resistant human HeLa Tet-off cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID696024Potentiation of doxorubicin-induced cytotoxicity in human KBV1 cells pre-incubated at 5 mM for 6 weeks before doxorubicin addition relative to untreated doxorubicin control2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID695819Reduction in P-gp protein expression in human HeLa MDR Tet-off cells at 10 mM incubated for 24 hrs by Western blotting2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205933Antibacterial activity against Escherichia coli BL21(DE3) cells harboring IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205933Antibacterial activity against Escherichia coli BL21(DE3) cells harboring IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205931Antibacterial activity against Escherichia coli BL21(DE3) cells harboring NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205931Antibacterial activity against Escherichia coli BL21(DE3) cells harboring NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID695858Cytotoxicity against human HEK293 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205930Binding affinity to hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells by X-ray crystallography2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205930Binding affinity to hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells by X-ray crystallography2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205928Binding affinity to hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205928Binding affinity to hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695830Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs in presence of P-gp inhibitor tariquidar by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695862Cytotoxicity against human OVCAR8 Tet-off cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695822Reduction in P-gp protein expression in human HeLa MDR Tet-off cells at 0.1 mM incubated for 24 hrs by Western blotting2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695870Cytotoxicity against drug-resistant Chinese hamster C5 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695833Stimulation of P-gp by ATPase assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695828Inhibition of MRP1 in human KB-V1 cells assessed as reduction in calcein-AM efflux at 20 mM2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID696027Reduction in P-gp expression in human KBV1 cells incubated at 5 mM for 6 weeks2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695860Cytotoxicity against drug-resistant human MCF7/VP16 cells expressing MRP1 incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205940Ratio of imipenim MIC to imipenim MIC in presence of compound for Pseudomonas aeruginosa T2226 expressing IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205940Ratio of imipenim MIC to imipenim MIC in presence of compound for Pseudomonas aeruginosa T2226 expressing IMP-7 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695864Cytotoxicity against human HeLa Tet-off cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695873Cytotoxicity against pleotropic drug-resistant human KAS cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695855Cytotoxicity against drug-resistant human H460/TX50 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695834Inhibition of P-gp in human KB-V1 cells assessed as effect on calcein-AM accumulation2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID695837Drug metabolism in aqueous solution assessed as drug oxidation incubated for 5 days2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID696026Potentiation of cisplatin-induced cytotoxicity in human KBV1 cells pre-incubated at 5 mM for 6 weeks before doxorubicin addition relative to untreated cisplatin control2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695879Reduction in P-gp protein expression in human MCF7/VP16 cells at 1 mM incubated for 24 hrs by Western blotting2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205927Binding affinity to hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205927Binding affinity to hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695852Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KB-8-5-11 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1205925Inhibition of hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205925Inhibition of hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1205935Antibacterial activity against Escherichia coli BL21(DE3) cells harboring VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205935Antibacterial activity against Escherichia coli BL21(DE3) cells harboring VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205937Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205937Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring NDM-1 at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695840Resistance index, ratio of IC50 for human H460 cells to IC50 for drug-resistant human H460/TX50 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID695863Cytotoxicity against multi drug-resistant human HeLa Tet-off cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205934Antibacterial activity against Pseudomonas aeruginosa T2226 expressing IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205934Antibacterial activity against Pseudomonas aeruginosa T2226 expressing IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205932Antibacterial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205932Antibacterial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID695849Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for pleotropic drug-resistant human KAS cells2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695825Induction of in ABCB1 mRNA cleavage in human HeLa MDR Tet-off cells at 1 mM incubated for 24 to 72 hrs by Northern blotting2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID695869Cytotoxicity against drug-resistant Chinese hamster 10193 cells expressing beta tubulin mutant incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695841Resistance index, ratio of IC50 for human HEK293 cells to IC50 for drug-resistant human HEK293 cells expressing MRP12011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID695850Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KB-A1 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695845Resistance index, ratio of IC50 for mouse NIH/3T3 cells to IC50 for drug-resistant mouse G185 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1205926Inhibition of hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205926Inhibition of hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID695842Resistance index, ratio of IC50 for human MCF7 cells to IC50 for drug-resistant human MCF7/VP16 cells expressing MRP12011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695847Resistance index, ratio of IC50 for CHO cells to IC50 for drug-resistant Chinese hamster 10193 cells expressing beta tubulin mutant2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (831)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990427 (51.38)18.7374
1990's168 (20.22)18.2507
2000's114 (13.72)29.6817
2010's97 (11.67)24.3611
2020's25 (3.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.47 (24.57)
Research Supply Index6.85 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index80.20 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (47.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials32 (3.51%)5.53%
Reviews36 (3.95%)6.00%
Case Studies76 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other768 (84.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]